



Sixth International Conference  
South-West University  
Faculty of Mathematics & Natural Sciences  
Blagoevgrad, Bulgaria 10 - 14 June, 2015

## SYNTHESIS AND ANTIVIRAL ACTIVITY OF SOME AMINO ACIDS DERIVATIVES OF INFLUENZA VIRUS DRUGS

<sup>1</sup>Radoslav Chayrov, <sup>1</sup>Vesela Veselinova, <sup>1</sup>Vasilka Markova,

<sup>2</sup>Luchia Mukova, <sup>2</sup>Angel Galabov, <sup>1</sup>Ivanka Stankova

South-West University "Neofit Rilski", Blagoevgrad, Bulgaria

<sup>1</sup>Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Science,  
Sofia, Bulgaria


**Abstract.** A series of new rimantadine (RS)-1-(1-adamantyl)ethanamine) analogues with some amino acids (alanine, valine, phenylalanine) have been synthesized and their antiviral activity against influenza A virus has been studied. Among the tested compounds the moderate antiviral activity has been found for the alanyl-rimantadine.

**Keywords:** Rimantadine, amino acids, influenza virus

### Introduction

Influenza A viruses are the major human pathogens that cause annual epidemics and occasional pandemics. In the past 100 years, influenza epidemic and pandemics had caused serious impact on global morbidity, mortality and economy. There are two subtypes of influenza A viruses based on the glycoproteins, hemagglutinin (HA) and neuraminidase (NA), which are found on the surface of the viral envelope (Chen et al., 2015). Currently, two classes of anti-influenza drugs are found on the market. Oseltamivir and zanamivir are the neuraminidase inhibitors. They block the active site of neuraminidase and allow stopping virus replication. There is another class drugs called M2 ion channel blockers. One of the currently available drugs for the prevention and treatment of influenza virus is amantadine and its analogue rimantadine. They inhibits the M2 proton channel of influenza A virus, yet most of the currently circulating strains of the virus carry mutations in the M2 protein that render the virus amantadine-resistant (Rey-Carrizo et al., 2014). The biological activity of adamantane derivatives is due to the symmetry and steric bulkiness of the structure and the significant lipophilicity of the rigid hydrocarbon framework. This enables them to penetrate easily through biological

membranes. Therefore, modification of organic compounds by an adamantyl radical changes significantly their biological activity, often enhancing it (Shibnev et al., 2012). The clinical usefulness of amantadine and rimantadine is limited due to the increasing incidence of adamantane-resistant viruses in the population (Bright, 2005). Moreover, the M2 ion channel blockers inhibit only influenza A virus replication and are associated with neurological side effects. Therefore we have synthesized and tested for antiviral activity against Influenza A viruses new amino acids derivatives of rimantadine (Fig. 1).



**Fig. 1.** M2 ion channel blockers - rimantadine (a) and amantadine (b)

Major problems of medicine besides the emergence of resistance it turns out and the potential passage of drug through the cell membrane and transfer it to the target cell (Griffiths & Sjövall, 2010). In order to facilitate the passage of biologically active compounds through the cell membrane is to connecting them with transport molecules. A good approach to solving this problem is modification of biologically active substances with  $\alpha$ -amino acids. They are harmless molecules since they build up every known protein of living organisms.

## Experimental

The rimandatine substance, amino acids, isobutyl chloroformate and the solvents were purchased from Sigma-Aldrich. Triethylamine (TEA) was purchased from Merck, Germany. TLC analysis was performed on aluminum silica gel sheets 60 F254 plates (Merck) and spots were detected using an UV lamp at 254 nm and/or ninhydrin reagent 2% solution. As eluting systems are used chloroform / methanol (95:5). All solvents were distillated before use.

### *Synthesis of rimantadine analogues*

The *tert*-butyloxycarbonyl (Boc) amino acids (Boc-Ala, Boc- Phe, Boc-Val) (69 mmol) were dissolved in 2 ml  $\text{CH}_2\text{Cl}_2$ . The solution was cooled to  $-10^\circ\text{C}$ , added TEA (69 mmol) and dropwise isobutyl chloroformate (69 mmol). The rimantadine (46 mmol)

were dissolved in 2 ml  $\text{CHCl}_3$ , added TEA (46 mmol). After 15 min the solutions were mixed and stirred for 30 min at -10°C. The reaction mixture was stirred for 1h at 0°C. The mixture was poured into 5%  $\text{NaHCO}_3$ , extracted with  $\text{CH}_2\text{Cl}_2$ , washed with brine, dried over  $\text{Na}_2\text{SO}_4$  and concentrated *in vacio*. The residues was purified by TLC on Kieselgel 60F<sub>254</sub> using the solvent system chloroform/ methanol (95:5). Boc-Ala-Rim- M.m.= 350. 9; Boc-Val-Rim - M.m.= 378; Boc-Phe-Rim- M.m.= 426.

The resulting white solid, Boc-Phe-rimantadine, Boc-Ala-rimantadine and Boc-Val-rimantadine were dissolved in 2 ml of 50% TFA/  $\text{CH}_2\text{Cl}_2$  and stirred at 0°C for 1h to remove the Boc group.

#### *Antiviral activity against influenza virus A(H3N2)*

*Cells:* MDCK

Cytotoxicity assay for determination of the 50 % cytotoxic concentrations ( $\text{CC}_{50}$ ) of test compounds in MDCK (Madin Darby canine kidney cell monolayers).

#### *Virus: Influenza A/H3N2 strain Aichi*


Viral suspension is from the collection of the section “Virology” of the “Stefan Angelov” Institute of Microbiology, Bulgarian Academy of Sciences. The virus is cultured in a maintenance environment DMEM (Dulbecco’s Modified Eagles’s Medium) (Gibco BRL, USA) with 0.5% fetal veal serum, 10 mM HEPES (Merk, Germany) and antibiotics (penicillin 100 UI / mL and streptomycin 100  $\mu\text{g}$  / mL) at 37 °C in the presence of 5% CO<sub>2</sub>. After seeding in microtitre plates, MDCK cells were incubated at 5 % CO<sub>2</sub>, 37 °C and 95 % humidity for 48 h. Thereafter, the cell culture medium was aspirated and serially diluted compound concentrations in fresh cell culture medium were added (100  $\mu\text{l}$ /well; 2 parallels/concentration, dilution factor 2). Six untreated wells were used as cell control (negative control). 72 h after compound addition and incubation cell were stained with a crystal violet/methanol solution. After dissolving away the stain, the optical density (OD) of individual wells was determined in a Dynatech microplate Photometer (550 /630 nm) and compared with the mean optical density of the 6 cell controls.

## **Results and discussion**


The modification of various biological active compounds with amino acids allows them to be hydrolyzed more quickly under the influence of plasma enzymes, thus leading to their transformation as prodrugs. On the other hand these compounds exhibited poor stability in aqueous solution as exemplified with esters of metronidazole, acyclovir, ganciclovir, corticosteroids. To overcome such problem is the use of adequately selected spacer groups (Stankova, 1999).

For our synthesis of amino acid derivatives of rimantadine we use mixed anhydrides peptide synthesis method. The mixed anhydride method of coupling used in peptide synthesis involves reaction of a protected amino or peptide acid with an alkyl chloroformate in the presence of a tertiary amine base to give the mixed carboxylic acid - carbonic acid anhydride. The anhydride is then reacted with an amine nucleophile, which is either an amino acid ester  $\alpha$  or a peptide ester, giving the protected peptide (Chen, 1987). The *tert*-butyloxycarbonyl group was removed by TFA at 0°C.


The synthetic rout for the preparation of amino acids derivatives of rimantadine is shown in Sheme 1. Boc-AA (1a-c) were dissolved in  $\text{CH}_2\text{Cl}_2$  to -10°C, added triethylamine (TEA) and isobutyl chloroformate. Rimantadine were dissolved in  $\text{CHCl}_3$  and the solutions were mixed, stirred to produce the Boc-amino acids analogues (2 a-c). The resulting white solid, Boc-AA were dissolved in TFA to remove the Boc group (3a-c). The ESI-MS analysis proved the identity of the final products (Figs. 2-4).




**Scheme 1.** Synthesis of rimantadine analogues with amino acids



**Fig. 2.** ESI-mass spectrum of *tert*-butyloxycarbonyl-alanyl-rimantadine.  
Mass-spectrum of Boc-Ala-Rim: 373.3  $[\text{M} + \text{Na}]^+$



**Fig. 3.** Mass spectrum of *tert*-butyloxycarbonyl-valyl-rimantadine. Mass-spectrum of Boc-Val-Rim: 401.4  $[\text{M} + \text{Na}]^+$



**Fig. 4.** Mass spectrum of *tert*-butyloxycarbonyl-phenylalanyl-rimantadine.  
Mass-spectrum of Boc-Phe-Rim: 449.4  $[\text{M} + \text{Na}]^+$

*Biological activity*

Initially the new analogues **3a-c** were evaluated for their antiviral activity towards influenza virus *A*(H3N2). Results of the antiviral screening of the amino acids analogues of rimantadine are shown in Table 1. Analogues of valine (**3b**) and phenylalanine (**3c**) with rimantadine do not show activity, and analogue of alanine exhibited a moderate activity.

**Table 1.** Antiviral activity and cytotoxicity of rimantadine derivatives

Compounds	Cytotoxicity (CC <sub>50</sub> )	IC <sub>50</sub>
Ala-Rim ( <b>3 a</b> )	200	39,45
Val-Rim ( <b>3 b</b> )	205.82	0
Phe-Rim ( <b>3 c</b> )	20.30	0

These results demonstrate that modification of rimantadine with aliphatic and aromatic amino acids does not lead to an antiviral effect compared to amino acids with guanidino group.

**Acknowledgment.** We gratefully acknowledge financial support from the South-West University “N. Rilski”, Blagoevgrad, Bulgaria (Project SRP A19/15).

**REFERENCES**

- Bright, R.A., Medina, M.J., Xu, X., Perez-Oronoz, G., Wallis, T.R., Davis, X.M., Klimov, A.I. (2005). Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. *Lancet*, *366*, 1175–1181.
- Chen, F.M., Lee, Y., Steinauer, R. & Benoiton, N L. (1987). Mixed anhydrides in peptide synthesis: a study of urethane formation with a contribution on minimization of racemization. *Canadian J. Chem.*, *65*, 613-618.
- Chen, X., Si, L., Liu, D., Proksch, P., Zhang, L., Zhou, D. & Lin, W. (2015). Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin. *European J. medicinal chem.*, *93*, 182-195.
- Griffiths, W.J. & Sjövall, S. (2010). Bile acids: analysis in biological fluids and tissues. *J. Lipid Res.*, *51*, 23-41.
- Rey-Carrizo, M., Barniol-Xicota, M., Ma, C., Frigolé-Vivas, M., Torres, E., Naesens, L. & Vázquez, S. (2014). Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus. *J. Medicinal Chem.*, *57*, 5738-5747.

- Shibnev, V.A., Garaev, T.M., Finogenova, M.P., Shevchenko, E.S. & Burtseva, E.I. (2012). Search for new drugs: some pathways to overcoming drug resistance of influenza a virus to adamantane derivatives. *Pharm. Chem. J.*, 46, 1-5.
- Stankova, I.S., Simeonov, M. F., Maxsimova, V., Galabov, A.S., Golovinsky, E (1999). Synthesis of some nucleosides analogues. *Z. Naturforschung*, 4(27), 76-83.

✉ **Dr. Ivanka Stankova** (corresponding author)

Department of Chemistry

South-West University “Neofit Rilski”

66 Ivan Michailov Str.

2700 Blagoevgrad, Bulgaria

E-mail: ivastankova@swu.bg